



OBIL/BSE/36/2020-2021

Oceanaa Biotek Industries Limited

CIN : L15549TN2005PLC057919

GSTIN : 33AAACO8057E1ZM

E : obil@oceanaabiotek.com

www.oceanaabiotek.com

To,

The Corporate Relations Department
The Bombay Stock Exchange Ltd,
P J Towers, 1st Floor,
Dalal Street,
Mumbai – 400 001

Dear Sir/Madam,

Ref: Scrip Code: **538019**

ISIN: **INE732P01018**

Sub: Submission of Standalone unaudited Financial Results for the quarter ended 31st December, 2020.

This is to inform you that the meeting of the Board of Directors was held on 12th February, 2021 to consider and approve the following

- Standalone Unaudited Financial Results for the quarterly ended on 31.12.2020.

The following documents are enclosed herewith:


- Standalone unaudited Financial Results for the quarter ended 31.12.2020.
- Limited Review Report signed by Statutory Auditor
- Certification by Managing Director as per Regulation 33(2)(a) of SEBI ((Listing Obligations and Disclosure requirements) Regulations, 2015.

The meeting commenced at 12.00 p.m. and concluded at 02:30 p.m.

Kindly update the above in your records.

For Oceanaa Biotek Industries Limited

T Xavier Jeyaraj
Managing Director
Encl: As above



Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
The Board of Directors
M/s OCEANAA BIOTEK INDUSTRIES LTD

Limited Review Report of the Unaudited Financial Results for the quarter ended 31st December, 2020

We have reviewed the accompanying Statement of Unaudited Financial Results of M/s. OCEANAA BIOTEK INDUSTRIES LIMITED ("the Company") for the quarter ended 31st December, 2020 and year to date from 1st April, 2020 to 31st December, 2020 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 ("the Regulation") as amended (the "Listing Regulations"), read with SEBI Circular No. CIR/CFD/CM1/80/2019 dated 19th July, 2019 ("the Circular").


This Statement which is the responsibility of the Company's Management and approved by the Board of Directors has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited Financial Results prepared in accordance with applicable Indian Accounting Standards specified under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Chennai
Date: 12/02/2021

For ABHAY JAIN & CO.
Chartered Accountants
FRN: 000008S


(A.K. Jain)

MNO: 070224

UDIN: 21070224AAAAAZ4608



M/S. OCEANAA BIOTEK INDUSTRIES LIMITED
CIN: L15549TN2005PLC057919
Flat No. C-4, Ceebros Apartments, No. 2, Saravana Street, T Nagar, Chennai - 600017

Unaudited Standalone Financial Results for the Quarter and Nine Months Ended 31st Dec 2020

(Rs in Lakhs)

S.No.	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		12/31/2020 (Unaudited)	9/30/2020 (Unaudited)	12/31/2019 (Unaudited)	12/31/2020 (Unaudited)	12/31/2019 (Unaudited)	3/31/2020 (Audited)
1	Revenue from Operations						
	a) Sale of products	90.34	354.04	327.87	897.85	1,307.26	2,565.50
	b) Other Operating Revenues						
	Total Revenue from Operations	90.34	354.04	327.87	897.85	1,307.26	2,565.50
2	Other Income	-	-	-	-	-	2.62
3	Total Income (1+2)	90.34	354.04	327.87	897.85	1,307.26	2,568.12
4	Expenses						
	a) Cost of Materials Consumed	33.75	128.52	106.69	323.00	268.94	1,063.77
	b) Purchase of Stock-in-Trade	-	-	-	-	171.28	-
	c) Changes in inventories of Finished Goods, Work-in-Progress and Stock-in-Trade"	101.32	44.25	7.20	65.88	38.11	(20.71)
	d) Employee Benefits Expense	23.24	33.38	26.10	79.56	95.12	130.84
	e) Depreciation and Amortisation Expense	46.18	46.18	54.45	137.95	162.75	216.60
	f) Finance Costs	1.21	1.49	1.74	4.36	5.84	7.57
	g) Other Expenses	30.09	77.08	40.61	266.25	220.03	920.84
	Total Expenses	235.78	330.90	236.79	877.00	962.08	2,318.91
5	Profit Before Exceptional Items and Tax (3 - 4)	(145.44)	23.14	91.08	20.85	345.19	249.21
6	Exceptional Items [Refer Note 4]	-	-	-	-	-	-
7	Profit Before Tax (5 + 6)	(145.44)	23.14	91.08	20.85	345.19	249.21
8	Tax Expense						
	i. Current Tax	-	3.62	1.89	26.12	18.33	-
	ii. Deferred Tax	0.41	0.41	21.11	1.05	24.50	(39.00)
	Total (i - ii)	(0.41)	3.21	(19.21)	25.07	(6.16)	39.00
9	Profit After Tax (7 - 8)	(145.03)	19.93	110.29	(4.22)	351.35	210.21
10	Other Comprehensive Income						
	"a) Items not to be reclassified to profit or loss in subsequent periods"	-	-	-	-	-	0.31
	"Re-measurement Gains and (Losses) on Defined Benefit Obligations (Net) and Net (Loss)/Gain on FVTOCI Equity Securities"	-	-	-	-	-	-
	Income Tax Effect	-	-	-	-	-	-
	"b) Items to be reclassified to profit or loss in subsequent periods"	-	-	-	-	-	-
	Net movement on cash flow hedges	-	-	-	-	-	-
	Income Tax Effect	-	-	-	-	-	-
	Other Comprehensive Income for the period	-	-	-	-	-	0.31
11	Total Comprehensive income (9 + 10)	(145.03)	19.93	110.29	(4.22)	351.35	210.52
12	Paid-up Equity Share Capital (Face Value of 10 Each)	135,652,750	135,652,750	135,652,750	135,652,750	135,652,750	135,652,750
13	Earnings Per Share (Face Value Rs. 10/- per Share) - Not Annualised						
	- Basic (in Rs.)	(1.07)	0.15	0.81	(0.03)	2.59	1.55
	- Diluted (in Rs.)	(1.07)	0.15	0.81	(0.03)	2.59	1.55

Notes:

- The Audited Financial results were reviewed by the Audit Committee and taken on record by the Board of directors at their meeting held on 12th Feb, 2021
- This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (IND AS) prescribed under Sec 133 of the Companies Act'2013 and other recognised accounting practices and policies to the extent applicable.
- Figures of the previous period/year are reclassified /regrouped or rearranged wherever necessary to make it comparable.
- There are no separate reportable segments for the Quarter ended Dec 2020 as per Accounting Standard 17 on segment reporting notified under the Companies (Accounting Standard) Rules 2014.
- There were no Investors' Complaints received during the period.
- All the financial numbers presented above are prepared as per the IND AS.
- The Company has considered the possible effects that may result from COVID-19 in the preparation of these standalone financial results including the recoverability of carrying amounts of financial and non-financial assets. In developing the assumptions relating to the possible future uncertainties in the global economic conditions because of COVID-19, the Company has, at the date of approval of these standalone financial results, used internal and external sources of information which are relevant and expects that the carrying amount of these assets will be recovered. The impact of COVID-19 on the Company's financial results may differ from that estimated as at the date of approval of these standalone financial results. However, the impact assessment of COVID-19 is a continuing process, given the uncertainties associated with its nature and duration. The Company will continue to monitor any material changes to future economic conditions and the consequent impact on its business, if any and make any necessary adjustments in the relevant financial period.

For and on Behalf of Board of Directors



Thomas Xavier Jeyaraj
Managing Director
DIN: 06896574

Place: Chennai
Date : 12-Feb-2021

Date: 12th February, 2021

DECLARATION

M/s Abhay Jain & Co., Chartered Accountants, Statutory Auditor of the Company have given an unmodified opinion with respect to the Standalone Unaudited Financial Results for the Quarter ended 31st December, 2020.

This declaration is submitted in compliance with Regulation 33 (3) (d) of the SEBI (Listing Obligations and Disclosure Requirements) (Amendments) Regulation, 2016, as issued by SEBI vide Notification No. SEBI/LAD-NRO/GN/2016-17/001 dated May, 25, 2016.

For Oceanaa Biotek Industries Limited



T Xavier Jeyaraj
Managing Director
Place: Chennai

For Abhay Jain & Co
Chartered Accountants
FRN: 000008S



CA A K JAIN
Partner
M No.: 070224


To
The Board of Directors,
Oceanaa Biotek Industries Limited

Dear Sir/Madam,

We hereby confirm the following in respect of the audited financial statements for the quarter ended on 31st December, 2020 being presented before the Board at the meeting to be held on 12th February, 2021.

- (1) That to the best of our knowledge, the financial results do not contain any false or misleading statement of figures.
- (2) That to the best of our knowledge, the financial results do not omit any material fact which may make the statements or figures contained therein misleading.

Yours sincerely



Place: **Chennai**
Date: **12.02.2021**

T Xavier Jeyaraj
Managing Director
DIN: 06896574